Sanofi
A global biopharmaceutical company that discovers, develops, and markets medicines and vaccines.
SAN | PA
Overview
Corporate Details
- ISIN(s):
- FR0000120578 (+39 more)
- LEI:
- 549300E9PC51EN656011
- Country:
- France
- Address:
- 46 AVENUE DE LA GRANDE ARMEE, 75017 PARIS
- Sector:
- Manufacturing
Description
Sanofi is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and marketing of therapeutic solutions. The company's portfolio includes a wide range of medicines and vaccines designed to improve human health. Sanofi focuses on several key therapeutic areas, including immunology, oncology, rare diseases, neurology, and vaccines. Emphasizing a research-driven approach, the company increasingly utilizes artificial intelligence to innovate and accelerate the delivery of new treatments for patients worldwide. Sanofi is also a producer of active pharmaceutical ingredients.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Type / Size | Actions | |
|---|---|---|---|---|---|
| 2023-03-23 07:00 |
Communiqué de presse: Dupixent® pourrait devenir le premier médicament biologiq…
|
French | PDF • 210.3 KB | ||
| 2023-03-23 07:00 |
Press Release: Dupixent® demonstrates potential to become first biologic to tre…
|
English | PDF • 204.5 KB | ||
| 2023-03-21 07:00 |
Press Release: Dupixent® (dupilumab) approved by European Commission as first a…
|
English | PDF • 200.6 KB | ||
| 2023-03-21 07:00 |
Communiqué de presse: Dupixent® (dupilumab) : premier et seul médicament ciblé …
|
French | PDF • 219.0 KB | ||
| 2023-03-18 15:00 |
Communiqué de presse: Des données de dernière heure sur Dupixent® (dupilumab) p…
|
French | PDF • 199.3 KB | ||
| 2023-03-18 15:00 |
Press Release: Dupixent® (dupilumab) late-breaking data at AAD show significant…
|
English | PDF • 184.5 KB | ||
| 2023-03-16 21:06 |
Communiqué de presse : Sanofi réduit de 78% le prix catalogue de Lantus®, son i…
|
French | PDF • 189.2 KB | ||
| 2023-03-16 21:06 |
Press Release: Sanofi cuts U.S. list price of Lantus®, its most-prescribed insu…
|
English | PDF • 164.5 KB | ||
| 2023-03-14 19:27 |
Informations relatives au nombre de droits de vote et d'actions – FEVRIER 2023
|
French | PDF • 118.7 KB | ||
| 2023-03-14 19:27 |
Information concerning the total number of voting rights and shares – February …
|
English | PDF • 142.1 KB | ||
| 2023-03-14 17:05 |
6-K
|
English | ZIP • 31.2 KB | ||
| 2023-03-13 16:40 |
S-8 POS
|
English | ZIP • 9.7 KB | ||
| 2023-03-13 12:38 |
6-K
|
English | ZIP • 33.2 KB | ||
| 2023-03-13 07:00 |
Communiqué de presse: Sanofi va acquérir Provention Bio, Inc. – une opération q…
|
French | PDF • 189.3 KB | ||
| 2023-03-13 07:00 |
Press Release: Sanofi to acquire Provention Bio, adding to portfolio TZIELD, th…
|
English | PDF • 168.1 KB |
Automate Your Workflow. Get a real-time feed of all Sanofi filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Sanofi
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Sanofi via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-05-02 | N/A | Other | Buy | 71,423 | N/A |
| 2024-04-26 | N/A | Other | Buy | 1,000 | 91,380.00 EUR |
| 2023-06-09 | N/A | Other | Buy | 9 | 856.04 EUR |
| 2023-05-02 | N/A | Other | Buy | 65,205 | 6,364,008.00 EUR |
| 2023-05-02 | N/A | Other | Buy | 500 | 48,835.00 EUR |
Peer Companies
